NYSE
Every company in the roster listed on NYSE.
Every company in the roster listed on NYSE.
23 of 23 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Eli LillyLLY · NYSE | 73 assets: 30 approved, 12 Ph 3, 16 Ph 2, 12 Ph 1, 3 other | eloralintidePhase 3 · ObesityReliable signal | Nov 2026Tirzepatide (Zepbound) · Phase 3 | $1.30T | $4.9BSep 2026 | Cash-flow positive | $15.4B |
Johnson & JohnsonJNJ · NYSE | 57 assets: 31 approved, 11 Ph 3, 4 Ph 2, 11 Ph 1 | SeltorexantPhase 3 · Major Depressive DisorderReliable signal | 8 Dec 2026Milvexian · Phase 3 | $656.5B | $17.2BSep 2026 | Cash-flow positive | $16.1B |
AbbVieABBV · NYSE | 78 assets: 22 approved, 9 Ph 3, 12 Ph 2, 25 Ph 1, 10 other | mesalamine (Asacol HD)US approval withdrawn · Ulcerative ColitisReliable signal | Nov 2026Budigalimab · Phase 2 | $505.6B | $10.8BSep 2026 | Cash-flow positive | $10.0B |
Merck & Co.MRK · NYSE | 54 assets: 19 approved, 19 Ph 3, 10 Ph 2, 3 Ph 1, 3 other | EnlicitidePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | Nov 2026Sacituzumab Tirumotecan · Phase 3 | $339.7B | $9.8BSep 2026 | Cash-flow positive | $30.8B |
NovartisNVS · NYSE | 89 assets: 32 approved, 13 Ph 3, 24 Ph 2, 12 Ph 1, 8 other | indacaterol maleate / mometasone furoatePhase 3 · AsthmaReliable signal | 27 Nov 2026Inclisiran · Approved | $294.9B | $11.5BDec 2025 | Cash-flow positive | $11.2B |
AbbottABT · NYSE | 1 asset: 1 Ph 3 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026Serplulimab · Phase 1 | $181.0B | $4.3BSep 2026 | Cash-flow positive | $3.3B |
Novo NordiskNVO · NYSE | 32 assets: 13 approved, 8 Ph 3, 5 Ph 2, 4 Ph 1, 2 other | repaglinideUS approval withdrawn · Type 2 DiabetesPartial signal | Dec 2026UBT251 · Phase 1 | $174.4B | $4.2BDec 2025 | Cash-flow positive | $7.9B |
PfizerPFE · NYSE | 95 assets: 43 approved, 19 Ph 3, 9 Ph 2, 13 Ph 1, 11 other | ecnoglutidePhase 3 · ObesityReliable signal | 29 Nov 2026Rimegepant (Nurtec ODT) · Phase 3 | $159.9B | $11.0BSep 2026 | Cash-flow positive | $11.5B |
Bristol-Myers SquibbBMY · NYSE | 61 assets: 23 approved, 9 Ph 3, 18 Ph 2, 9 Ph 1, 2 other | MezigdomidePhase 3 · Multiple MyelomaPartial signal | Nov 2026Izalontamab brengitecan · Phase 3 | $121.9B | $12.6BSep 2026 | Cash-flow positive | $10.6B |
GlaxoSmithKlineGSK · NYSE | 73 assets: 26 approved, 8 Ph 3, 10 Ph 2, 10 Ph 1, 19 other | VilanterolPhase 3 · AsthmaPartial signal | 23 Nov 2026Dostarlimab · Phase 2 | $104.8B | $4.6BDec 2025 | Cash-flow positive | $9.9B |
Takeda Pharmaceutical CompanyTAK · NYSE | 42 assets: 20 approved, 12 Ph 3, 6 Ph 2, 2 Ph 1, 2 other | zasocitinibPhase 3 · Psoriatic ArthritisReliable signal | Nov 2026Mirvetuximab soravtansine · Phase 2 | $67.7B | — | Profitable | $4.1B |
Teva Pharmaceutical IndustriesTEVA · NYSE | 13 assets: 10 approved, 2 Ph 3, 1 Ph 1 | Dexmedetomidine (Igalmi)Phase 3 · SchizophreniaReliable signal | 15 Jan 2027Emrusolmin · Phase 1 | $49.8B | $4.1BSep 2026 | Cash-flow positive | $1.8B |
Dr. Reddy's LaboratoriesRDY · NYSE | 4 assets: 2 approved, 2 Ph 3 | PyrotinibPhase 3 · Non-Small Cell Lung CancerPartial signal | Nov 2026Pyrotinib · Phase 1/2 | $12.5B | $172MMar 2025 | Cash-flow positive | $323M |
Bausch HealthBHC · NYSE | 15 assets: 13 approved, 1 Ph 3, 1 Ph 2 | Rifaximin SSDPhase 3 | 20 Apr 2027Rifaximin (Xifaxan) · Approved | $3.3B | $2.5BSep 2026 | Cash-flow positive | $638M |
BiohavenBHVN · NYSE | 7 assets: 5 Ph 3, 1 Ph 2, 1 Ph 1 | TroriluzolePhase 3 · Spinocerebellar AtaxiaPartial signal | Dec 2026Opakalim · Phase 2/3 | $1.9B | $164MSep 2026 | ~1.4 qtrs | $428M |
Nuvation BioNUVB · NYSE | 2 assets: 1 approved, 1 Ph 3 | safusidenibPhase 3 · Glioma | 2 Feb 2027Taletrectinib · Phase 1 | $1.3B | $663MSep 2026 | ~25.0 qtrs | $133M |
Alto NeuroscienceANRO · NYSE | 6 assets: 6 Ph 2 | ALTO-100Phase 2 · Major Depressive DisorderPartial signal | Dec 2026ALTO-300 · Phase 2 | $1.2B | $320MSep 2026 | ~16.2 qtrs | $73M |
EvommuneEVMN · NYSE | 3 assets: 3 Ph 2 | EVO101Phase 2 · Atopic DermatitisPartial signal | Oct 2027EVO756 · Phase 2 | $284M | $170MSep 2026 | ~7.5 qtrs | $89M |
Emergent BioSolutionsEBS · NYSE | 3 assets: 3 approved | Approved assets only | None on record | $283M | $177MSep 2026 | Cash-flow positive | $41M |
Maia BiotechnologyMAIA · NYSE | 1 asset: 1 Ph 3 | Ateganosine (THIO)Phase 3 · Non-Small Cell Lung Cancer | 31 Jul 2027Ateganosine (THIO) · Phase 3 | $79M | $0Sep 2026 | Ended Sep 2026 | -$2.7M |
Palatin TechnologiesPTN · NYSE | 3 assets: 1 Ph 3, 2 Ph 2 | PL9643Phase 3 · Dry Eye DiseasePartial signal | None on record | $20M | $7.5MJun 2026 | ~2.2 qtrs | $12M |
Amneal PharmaceuticalsAMRX · NYSE | 6 assets: 6 approved | Approved assets only | None on record | — | $180MSep 2026 | Cash-flow positive | $181M |
OrganonOGN · NYSE | 12 assets: 11 approved, 1 other | Atozet (ezetimibe/atorvastatin)Atherosclerotic Cardiovascular Disease | Aug 2027Tapinarof · Phase 3 | — | $1.5BSep 2026 | Cash-flow positive | $357M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.